Satou Shinji

Փ��

Clinical characteristics of four myositis-specific autoantibodies with regulatory-approved testing in Japan: A Japanese multi-centre adult myositis patients' cohort.

Risk prediction modeling based on a combination of initial serum biomarkers in myositis-associated interstitial lung disease.

Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study.

Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus

EVALUATION OF DIAGNOSTIC PERFORMANCE OF MAGNETIC RESONANCE IMAGING (MRI) AND ULTRASOUND (US) TOWARD EARLY RHEUMATOID ARTHRITIS FROM NAGASAKI EARLY ARTHRITIS COHORT

PREDICTION OF RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS BY BOTH MAGNETIC RESONANCE IMAGING AND ULTRASOUND

Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis

Influence of Season and Residential Environment on Development of Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis with Interstitial Lung Disease

Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis

Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies

Aggregation of rare/low-frequency variants of the mitochondria respiratory chain-related proteins in rheumatoid arthritis patients.

Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.

Exome sequencing identifies novel rheumatoid arthritis-susceptible variants in the BTNL2.

1. Exome sequencing identifies novel rheumatoid arthritis-susceptible variants in the BTNL2.

��ͬ�о�?�������Y��Ȥ��о��n�}

Clarification of pathogenesis in patients with dermatomyositis and rapidly progressive interstitial lung disease for new therapeutic approach

Clarification of pathogenesis in patients with dermatomyositis and rapidly progressive interstitial lung disease for new therapeutic approach

Pathogenic role of CADM-140 antigen (MDA5) in patients with dermatomyositis

Clinical application of anti-CADM-140 antibodies detected inpatients with dermatomyositis